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1201-Cyclical variation of blood pressure and heart rate in neonates EDITOR,-We read with interest the recent article by Cunningham et al on the cyclic variation of blood pressure and heart rate in neonates.1 Despite a lengthy discussion of the possible aetiologies they conclude 'we have been unable to identify any factors that might have convincingly induced the waves ...'. We have observed similar cyclic changes that were due to causes not apparently discussed in the article: unrecognised bolus administration of vasoactive drugs and seizures. Continuous infusion syringe pumps used in neonatal intensive care often deliver a series of small boluses due to the syringe plunger 'sticking' in the barrel. This problem is caused by the syringe, rather than the pump. We have observed that the phase relatior,ship between heart rate and blood pressure changes is influenced by the nature of the drug being administered. Figure 1 shows an in-phase response due to the bolus delivery of dopamine, while fig 2 shows an out-of-phase response due to the bolus delivery of morphine. Cunningham et al report that they observed an association between the use of morphine and the cyclic pattern,' and while they made no comment on the use of an inotrope, it is possible that an inotrope was administered given that 'blood volume support was needed (by 50% of the babies) during the wave episodes'.
Data from a neonate displaying seizure behaviour, and on no vasoactive medication, is shown in fig 3. Here a complex phase relationship exists between the heart rate and blood pressure. Of the 10 neonates reported by Cunningham et al to show the cyclic behaviour,' seven were hypocalcaemic, eight had asphyxia, some were receiving morphine (itself a possible cause of seizures), and the waves could 'be altered just by touching the baby'. The cause of the cyclic behaviour may have been seizure activity.
Until iatrogenesis or seizures are excluded as causes we remain unconvinced that 'blood pressure waves ... equivalent to 50% of resting pressure' are likely to be due to physiological control mechanisms. Time of day Figure 2 Out-of-phase cyclic behaviour due to the bolus delivery of morphine. Archives ofDisease in Childhood 1994; 70: F78 less than 32 weeks' gestation (with an out-ofphase response) were all receiving morphine, this was indeed the case: nine of the 10 infants described were receiving morphine by intravenous infusion (10 p.g/kg/hour) as per unit policy. However, only one of the infants with an in-phase relation were receiving inotropic support at the start of their wave episodes. As we suggested, it would appear strange that electromechanical causes could be stopped by merely gently touching the infant.
Infants with overt seizures have been captured many times on our continuous computerised physiological monitoring system, though none have displayed a regular cyclical pattern in heart rate and blood pressure during a convulsion. Seizures were noted in four of the infants described, though only one demonstrated overt seizures during a wave episode. Since the paper was submitted, a further infant has been investigated by 24 hour EEG during a prolonged period of blood pressure waves: no evidence of seizure activity was recorded.
Adverse experiences in an Exosurf treated group EDiTOR, The results of recent trials using artificial surfactant for premature neonates with hyaline membrane disease have yielded convincing evidence of efficacy, and are likely to lead to widespread use.l1 We have used Exosurf (Wellcome) in 54 babies as part of the OSIRIS multicentre trial5 and were concerned to witness some adverse experiences in a proportion of these babies. We noted an increase in the incidence of lobar collapse and consolidation and blocked endotracheal tubes, resulting in clinical and radiological deterioration. While we would emphasise that it would not be proper to draw any conclusions from our observations, we suggest that they do give rise to some cause for further investigation.
We have seen this problem in babies of varying weights and gestation, not just very low birthweight babies. Decreasing the rate of administration of Exosurf did not seem to improve tolerance and the large volume administered, 5 ml/kg, seemed to be a factor. Because of our concern over the acute deteriorations coinciding with the administration of Exosurf we have looked more closely at the outcome in our Exosurf treated group and compared various outcome measures with a historical group, treated before we entered the OSIRIS trial, of babies matched for birth weight, gestation, and A/a ratio.
We found that the babies treated with
Exosurf were ventilated for a significantly longer period of time (7 days 
